On June 21st, the training session “How to support researchers in writing competitive proposals for Horizon 2020” was held at the Duran i Reynals hospital. The course, part of the ICABELL project, was taught by Dr. Sean McCarthy, expert in European funding for research projects. The session, which had a high degree of attendance, […]
Specialised training session for H2020 project managers Read More »
A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival
New combined treatment shows promise in Hepatocellular Carcinoma Read More »
Cisplatin is one of the chemotherapeutic agents more frequently used by oncologists to treat tumors. Cisplatin-based chemotherapy is very efficient but frequently cancer cells adjust its molecular mechanisms to become resistant to cisplatin. The IDIBELL research group “Modeling Human diseases in C. elegans”, led by Julián Cerón, have been using a microscopic worm to investigate
Ernest Nadal and Samuel Gonçalves are awarded research grants to advance in cancer research
Two new AECC grants for IDIBELL researchers Read More »
In recent years, immunotherapy has been consolidated as one of the new and principal hopes in the fight against cancer. This therapeutic approach is based on the fact that our immune system is constantly watching the presence of strange presences within the body and fighting them. When a tumor originates, its mutations make cancer cells
New discoveries towards the improvement of the immunotherapy treatment of lung cancer Read More »
The clinical application of an inhibitor of the SHP2 protein (also called PTPN11) could be effective, in the near future, in patients affected by one of the main types of lung cancer, the so-called Non-small cell lung cancer (NSCLC). This is the conclusion reached by an international research team including doctors Alberto Villanueva and Ernest
New drug against of the main types of lung cancer Read More »
A new study by doctor Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of Barcelona, presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL), a type of cancer characterized by
New epigenetic drug against Mantle Cell Lymphoma Read More »
Experts from the Institute of Neurosciences of the University of Barcelona (UB), the Bellvitge Biomedical Research Institute (IDIBELL) and Universitat Autònoma de Barcelona (UAB) design the first photoactive drug to fight Parkinson’s disease.
First photoactive drug to fight Parkinson’s disease Read More »
